Advertisement

Topics

Companies Related to "Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer" [Most Relevant Company Matches] RSS

06:11 EST 20th February 2019 | BioPortfolio

Here are the most relevant search results for "Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer" found in our extensive corporate database of over 50,000 company records.

Showing "Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors" Companies 1–25 of 2,400+

Extremely Relevant

Globe Laboratories

Globe Labs manufactures and sells high quality, low cost human therapeutic proteins, human growth hormones, enzymes, research laboratory cytokines, chemokines & their respective inhibitors/antagonists for research and veterinary use. We are also manufacturers of bulk quantities for other pharmaceutical companies worldwide. Globe Labs is proud to have the largest antagonist product list in the worl...


ArQule, Inc.

ArQule is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company’s targeted, broad-spectrum products and research programs are focused on key biological processes that are central to human cancers. ArQule’s lead product, in Phase 2 clinical development, is ARQ 197, an in...

Forbius

Forbius is a clinical stage company that designs and develops biotherapeutics for the treatment of cancer and fibrotic diseases. Forbius’ medicines are designed to radically transform patients’ lives. We use our strength in biological understanding and diverse protein engineering technologies to design superior inhibitors of validated pathways. W...


BTI

BTI has been manufacturing growth factor (GF) and attachment factor (AF) products since 1981. Our extensive product line includes receptor-grade, aseptically packaged GFs and AFs. These are highly purified proteins that have been membrane filtered, aseptically filled and lyophilized. Most BTI GFs have been tested in cell culture, receptor binding studies and in immunoassays. Some GFs are availa...

SGX Pharmaceuticals, Inc.

SGX Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development and commercialization of novel, targeted therapeutics directed at addressing unmet medical needs in oncology. Our drug development programs target the MET receptor tyrosine kinase, an enzyme implicated in a broad array of cancers, and the BCR-ABL tyrosine kinase enzyme for the treatment of Chronic Myelog...

Hana Biosciences, Inc.

Hana Biosciences, Inc. (Nasdaq: HNAB) is a biopharmaceutical company dedicated to developing new, differentiated cancer therapies designed to improve and enable current standards of care. The Company has two lead product candidates that target large markets and are in pivotal and/or proof-of-concept clinical trials. Marqibo(R) is being developed to treat lymphoid cancers such as ALL and lymph...

CellZome AG

Cellzome is a privately-owned drug discovery company identifying a new generation of kinase- targeted drugs to treat inflammatory diseases. Its pipeline of small-molecule therapeutics is driven by Kinobeads™, a proprietary technology for the screening and profiling of kinases in relevant cells and tissues. Cellzome's emerging pipeline includes a small molecule Histamine H4 receptor antagonist, ...

OSI Pharmaceuticals

OSI Pharmaceuticals is committed to “shaping medicine and changing lives” by developing and commercializing high-quality and novel pharmaceutical products that extend life or improve the quality of life for patients with cancer, diabetes, and obesity. We specialize in the discovery and development of innovative molecular targeted therapies that address significant unmet medical needs, and st...

YM BioSciences Inc

YM BioSciences Inc. is an oncology company that identifies, develops and commercializes differentiated products for patients worldwide. The Company is advancing two late-stage products: nimotuzumab, a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR) and is approved in several countries for treatment of various types of head and neck cancer; and AeroLEF™, a p...

Minerva Biotechnologies

Minerva Biotechnologies is a pioneer in the field of stem cells and cancer stem cells. Minerva was first to discover that cancer cells hijack an otherwise normal stem cell growth mechanism, involving a growth factor receptor called MUC1* (pronounced muk 1 star). By studying human stem cells in parallel with human cancer cells, Minerva scientists figured ou...

Relevant

Ziarco

Ziarco is a clinical-stage biotechnology company developing innovative therapeutics targeting inflammatory and allergic diseases. The company’s product pipeline includes ZPL-3893787, an H4 receptor antagonist that has completed a Phase 1 multiple ascending dose study. A second clinical-stage, programme targets inflammatory disorders by inhibiting cyto...

Inflection Biosciences Ltd

Inflection Biosciences Ltd, based in Dublin and London, is developing small molecule therapeutics for the treatment of cancer. The company's pipeline of highly innovative cancer treatments was licensed from the Spanish National Cancer Research Centre (CNIO). The pipeline comprises the IBL-300 series (PIM/PI3K/mTOR inhibitors) and IBL-202 (PIM/PI3K inhibito...

CBT Pharmaceuticals, Inc.

CBT Pharmaceuticals is a biopharmaceutical company focused on developing innovative oncology therapeutics harnessing the immune system and targeting specific molecular pathways to tame cancer. The company is advancing a pipeline of four development-stage assets. CBT-101, is an oral c-MET inhibitor targeting the epithelial to mesenchymal transition (EMT) pa...

PanVera Corporation

Protein Kinase C Assays Androgen Receptor, Ligand Binding Domain Estrogen Receptor-Beta 1, Long Form Tau Protein, microtubule-associated protein, histidine-tagged Cytochrome P450 Monoclonal Antibodiesa broad selection of antibodies can be found here.

Ambit Biosciences Corporation

Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease, and other indications. Ambit employs a novel and proprietary kinase profiling technology, KINOMEscan(TM), to screen compounds against 442 human kinases.

Puma Biotechnology, Inc.

Puma Biotechnology, Inc. is a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of various forms of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those ...

CBT Pharmaceuticals

CBT Pharmaceuticals is a life sciences company developing innovative oncology therapeutics targeting the growth and proliferation of cancer cells. The company is advancing a pipeline of four development-stage assets including CBT-101, an oral c-Met inhibitor targeting the epithelial-mesenchymal transition (EMT) pathway in cancers and CBT-501, a novel human...

Cellzome Inc.

Cellzome is a privately-owned drug discovery and development company identifying a new generation of kinase-targeted drugs to treat inflammatory diseases. Its pipeline of small-molecule therapeutics is driven by Kinobeads(TM), a proprietary technology for the screening and profiling of kinase inhibitors in physiologically-relevant cells and tissues. The most advanced program, targeting PI3K(ga...

NephRx Corporation

NephRx Corporation is a biotechnology company dedicated to the discovery and development of therapeutic products for the treatment of acute kidney failure and other renal disorders and diseases of the gastrointestinal tract, including mucositis, Crohn's disease and ulcerative colitis. Lead product NX001 is a kidney growth factor peptide for acute renal failure that is currently in preclinical dev...

Tyrosine Pharma, Inc.

Tyrosine Pharma, Inc., is a New Mexico-based biotech start-up company and a New Mexico Angels Technology Showcase Company. Visit www.tyrosinepharma.com for additional information.

Ocular Therapeutix™, Inc.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel-based formulation technology. Ocular Therapeutix’s lead product candidate, DEXTENZA™ (dexamethasone insert) 0.4 mg for intracanalicular ...

Otava Ltd

OTAVA, Ltd. offers unique Receptor-Based Target-Focused libraries. These libraries are created from an extensive compound stock collection (490,000 compounds) and a rigorous process of refinement that involves harnessing the most current methods of theoretical medicinal chemistry. All of the Receptor-Based Target-Focused libraries of compounds are available in-house, and come with docking scores a...

Biomed Comm Incorporated

Biomed Comm TM (BMC) was founded in May 1996 to manufacture Dr.Brewitt's proprietary growth factor products known as Cell Signal Enhancers® (CSE®). The company's homeopathic growth factors represent a new class of medicines combining today's advanced biotechnologies, electro-magnetic field theory and basic homeopathic principles formed over two centuries ago. Biomed CommTM currently manufact...

IBT

ibt develops, manufactures and distributes reagents (monoclonal and polyclonal antibodies, proteins, peptides, antigens) for infectious disease research, transcription, growth factor and cytokine research and assay kits for the detection of growth factors, e.g. insulin-like growth factors (IGF´s) and insulin-like growth factor binding proteins (IGFBP´s).

Step Pharma

Step Pharma is focused on the development of a novel class of oral nucleotide synthesis inhibitors targeting CTPS1 for the improved treatment of a range of autoimmune diseases. The company has identified several series of CTPS1 inhibitors, with the most advanced series currently undergoing lead optimization.


More From BioPortfolio on "Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks